ASX:ACR

Acrux (ACR) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
4,000 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
11.66%
Price Target
N/A
ACR stock logo

About Acrux Stock (ASX:ACR)

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of males. It also provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; and lidocaine and prilocaine cream, a generic version of EMLA cream, which is indicated as a topical anaesthetic for use on normal intact skin for local analgesia, and genital mucous membranes for superficial minor surgery and as a pre-treatment for infiltration anaesthesia. The company was incorporated in 1998 and is based in West Melbourne, Australia.

ACR Stock News Headlines

The “Next Bitcoin”? 10 CENT Crypto Set to Explode
The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…
The “Next Bitcoin”? 10 CENT Crypto Set to Explode
The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…
‘Poker star’s’ luxury yacht sunk by fire
See More Headlines
Receive ACR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acrux and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2019
Today
4/26/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
2,018
Year Founded
N/A

Profitability

Net Income
$-7,660,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$11.42 million
Book Value
A$0.02 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.19
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

ACR Stock Analysis - Frequently Asked Questions

How were Acrux's earnings last quarter?

Acrux Limited (ASX:ACR) released its quarterly earnings results on Thursday, February, 21st. The company reported ($0.02) earnings per share for the quarter. Acrux had a negative net margin of 6.21% and a negative trailing twelve-month return on equity of 12.21%.

Is Acrux a good dividend stock?

Acrux (ASX:ACR) pays an annual dividend of A$0.09 per share and currently has a dividend yield of 11.66%. ACR has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.

What other stocks do shareholders of Acrux own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acrux investors own include ANZ Group (ANZ), Lynas Rare Earths (LYC), Altium (ALU), Atlas Iron (AGO), Hugo Boss (BOSS), BHP Group (BHP), Beacon Roofing Supply (BECN), Billabong International (BBG), Abraxas Petroleum (AXAS) and Ausdrill (ASL).

This page (ASX:ACR) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners